Healthcare · Medical Devices · SE
Vitrolife AB VITR
kr120.10 · close of Nov 6, 2026
AI score · Average · analysis Dec 21, 2025
5.5 of 10
Risk holds this up; Optionality is the soft spot.
| Moat | 5.0 |
| Management | 5.0 |
| Valuation | 5.0 |
| Risk · 10 = lowest | 8.0 |
| Business model | 5.0 |
| Optionality | 5.0 |
Fair value
AI fair value
—
Base case
—
the single most likely path
Analyst consensus
—
12-month target
Price
kr120.10
The business
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Last report Oct 22, 2026 · next Jan 28, 2027
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no cardGeneral investment analysis · not personalized advice · the figures carry their dates